All News

Matt Sample, senior vice president of manufacturer, quality, and replenishment operations at Cencora, discusses DSCSA compliance hurdles, VRS tools, and a new push toward 12-digit NDCs.

Phase 3 data show subcutaneous risankizumab boosts remission and endoscopic healing in moderate-to-severe Crohn cases, with familiar safety and easier dosing.

FDA targets telehealth ads for compounded glucagon-like peptide-1s, warning of misleading claims, hidden sources, and safety risks amid social media hype.

FDA expands lomitapide use to children 2 years and older, highlighting major low-density lipoprotein reductions.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

A large study links an early A1c under 6.5% to fewer eye and nerve complications, urging pharmacists to intensify control and monitor retinopathy.

The FDA expands the drug's usage to treat idiopathic short stature, small for gestational age, and growth failure associated with Noonan syndrome.

The event will explore how community pharmacy leaders can improve profitability, business resilience, as well as PBM and reimbursement challenges.

Pharmacists can close the gap between recommendations and uptake for pregnant women.

Orforglipron beats oral semaglutide in A1C and weight loss in a head-to-head study for type 2 diabetes.

Long-term care pharmacists shift to safety-first care by deprescribing anticholinergics, using dysphagia-friendly forms, and raising vaccination rates.

Navitus Health Solutions conducted a survey of 2000 US adults who have been taking glucagon-like peptide-1 therapies for the past 2 years.

In part 2 of our conversation with CLIAwaived Inc CEO Tim Drapeau, we explored the future horizons in community pharmacy and how at-home testing is advancing the pharmacist’s role in health care.

Three-year QUASAR data show guselkumab keeps most ulcerative colitis patients in remission, with strong healing rates and no new safety issues.

Upon approval, dupilumab becomes the first and only medication on the market to target adult and pediatric patients’ allergic fungal rhinosinusitis.

Novo Nordisk’s CagriSema drives 23% weight loss in REDEFINE 4 but misses noninferiority compared with tirzepatide, shaping the next wave of obesity drugs.

In a post-hoc analysis, researchers testnm the effects of tezepelumab against placebo among patients with severe uncontrolled asthma.

Tim Drapeau, CEO of CLIAwaived Inc, discusses his company’s new Test Yourself @ Home diagnostics kit and how it’s advancing the role of community pharmacy in real time.

The FDA approves Bysanti (milsaperidone) for schizophrenia and bipolar I disorder, leveraging iloperidone bioequivalence, with key metabolic monitoring needs.

New data links glucagon-like peptide-1s to fewer aneurysm ruptures and lower death risk, guiding pharmacists on safer stroke prevention.

Pharmacists help explain the complex evidence, address fears around injections and cost, and help patients integrate lifestyle changes alongside pharmacologic therapy for diabetes care.

Just before monumental PBM reform was signed into law, as well as a landmark settlement between the FTC and Express Scripts, the Department of Labor proposed its own set of PBM regulations.

Using the PRIME program’s framework, researchers explore a digital-health and pharmacy-based lifestyle intervention for improving risk factors among patients with prediabetes.

Community pharmacists strengthen disaster response by coordinating vaccines, bridging care gaps, and securing lifesaving meds under pressure.

Pharmacists help turn Food Is Medicine into covered care, linking heart patients to tailored meals, produce prescriptions, and easier chronic disease prevention.

In a reversal of its refusal-to-file letter issued last week, the FDA decides to move forward with Moderna’s mRNA flu vaccine developments.

Amid common patient threats stemming from severe hypoglycemia, researchers explore how proactive pharmacist outreach can translate to safer prescribing regimens for patients with diabetes.

Jeff Goad, PharmD, MPH, joins Drug Topics to discuss potential COVID-19 vaccine removal and what it could mean for the future of mRNA vaccine technology.